EuroBiotech Report: More Articles Of Note

> Belgian biotech Bone Therapeutics (EBR:BOTHE) raised €32.2 million ($36.6 million) in an oversubscribed IPO. The Euronext listing was 2.5 times oversubscribed and attracted "more than 50 new high quality European institutional and private investors," CEO Enrico Bastianelli said. Bone Therapeutics will use the money to fund mid-phase trials of its bone cell products. PharmaTimes

> Summit (AIM:SUMM) submitted its paperwork to list on Nasdaq. The British biotech is heading to the U.S. in search of $40 million (€35 million) to finance early to mid-phase trials of its drugs against Duchenne muscular dystrophy and Clostridium difficile infection. FierceBiotech

> Transatlantic biotech Motif Bio outlined plans to raise up to £16 million ($24 million) in an IPO on London's AIM market. Motif Bio started life in 2003 as a New York-based population genetics firm built upon genome data from the Gulf states, but has pivoted into a transatlantic antibiotics player over the past few years. The IPO will accelerate this process by allowing Motif Bio to acquire iclaprim, an antibiotic that the FDA rejected in 2009. Reuters

> Bloomberg took a look at the work of the research firms that can trigger surges in the shares of small biotechs. The investigation was prompted by a 39% jump in the stock of Pluristem Therapeutics ($PSTI), an Israeli stem cell business. Bloomberg linked the uptick back to the publication of a report by Acceleron Equity Research but was unable to ascertain the identity or credentials of its author. Bloomberg

> Pharmasum Therapeutics bagged a NOK 12 million ($1.6 million) grant to get its Alzheimer's disease program up and running. The ex-GlaxoSmithKline ($GSK) staffers running the outfit are aiming to raise a further NOK 5 million in private funding, select a lead candidate in 12 months' time and be bought out within 7 years. Release

> PharmaMar and partner Johnson & Johnson ($JNJ) secured a priority review for their long-delayed cancer drug Yondelis. The priority status cuts the drug's review time from 10 to 6 months, inching it closer to approval 5 years after it was first formally rejected by FDA. J&J has the rights to sell the drug outside of Japan and Europe. Release

> Vectura (LSE:VEC) CEO Dr. Chris Blackwell revealed he will step down in June. Blackwell joined the company in 2002 and took over as CEO shortly before it went public two years later. Vectura--which first rose to prominence as a developer of "inhalable Viagra"--now has partnerships with Janssen Biotech, Novartis ($NVS) and other major biopharma businesses. Release